EP 1071808 A1 20010131 - TELOMERASE ASSAY OF BODY FLUIDS FOR CANCER SCREENING AND ASSESSMENT OF DISEASE STAGE AND PROGNOSIS
Title (en)
TELOMERASE ASSAY OF BODY FLUIDS FOR CANCER SCREENING AND ASSESSMENT OF DISEASE STAGE AND PROGNOSIS
Title (de)
TELOMERASETEST VON KÖRPERFLÜSSIGKEITEN ZUM SCREENEN, ZUR FESTSTELLUNG DES KRANKHEITSSTADIUMS UND DER PROGNOSE VON KREBS
Title (fr)
DOSAGE DE TELOMERASE PRELEVE DANS DES LIQUIDES ORGANIQUES UTILISE POUR LE DEPISTAGE DU CANCER, L'EVALUATION DU STADE D'EVOLUTION DE LA MALADIE ET L'ETABLISSEMENT DU PRONOSTIC
Publication
Application
Priority
- US 9903302 W 19990216
- US 7479398 P 19980216
Abstract (en)
[origin: WO9941406A1] Elevated telomerase activity levels in tissue and cell extracts have been used to determine the presence of cancer in a tissue sample. The invention herein is directed to an improved telomeric repeat amplification protocol (TRAP) assay for quantitating telomerase RNA or telomerase activity levels, using easily obtainable body fluids, such as blood, plasma, lymph, pleural fluid, spinal fluid, saliva, sputum, urine, and semen, for example, to both detect the presence of cancer as well as assess the stage of the disease and the prognosis of the patient. The improved TRAP assay can be used as a diagnostic marker for malignancy as well as a means of monitoring the progress and effectiveness of cancer therapies.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); C12P 19/34 (2006.01); C12Q 1/68 (2006.01); C12Q 1/6886 (2018.01)
CPC (source: EP)
C12Q 1/6886 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01)
Citation (search report)
See references of WO 9941406A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9941406 A1 19990819; AU 2682299 A 19990830; CA 2321259 A1 19990819; EP 1071808 A1 20010131; JP 2002503480 A 20020205
DOCDB simple family (application)
US 9903302 W 19990216; AU 2682299 A 19990216; CA 2321259 A 19990216; EP 99907069 A 19990216; JP 2000531587 A 19990216